9788419284365.Lenhan_Manual Washington de Cardiooncología

123

Capítulo 8 Trombosis y embolias asociadas al cáncer

REFERENCIAS 1.Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood . 2013;122(10):1712-1723. 2.Navi BB, Reiner AS, Kamel H, et al . Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol . 2017;70(8):926-938. 3.Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. romboem bolism in hospitalized neutropenic cancer patients. J Clin Oncol . 2006;24(3):484-490. 4.Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. romboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J romb Haemost . 2007;5(3):632-634. 5.Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) . 2018; 10(10):380. 6.San lippo KM, Luo S, Wang TF, et al . Predicting venous thromboembolism in mul tiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol . 2019;94(11):1176-1184. 7.Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al . Hospitalisation for venous throm boembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer . 2010;103(7):947-953. 8.Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. er Adv Drug Saf . 2012;3(5):255-266. 9.Palumbo A, Rajkumar SV, Dimopoulos MA, et al . Prevention of thalidomide and lenalido mide-associated thrombosis in myeloma. Leukemia . 2008;22(2):414-423. 10. Leleu X, Attal M, Arnulf B, et al . Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood . 2013;121(11):1968-1975. 11. Stewart AK, Rajkumar SV, Dimopoulos MA, et al . Car lzomib, lenalidomide, and dexame thasone for relapsed multiple myeloma. N Engl J Med . 2015;372(2):142-152. 12. Bradbury CA, Craig Z, Cook G, et al . rombosis in patients with myeloma treated in the Mye loma IX and Myeloma XI phase 3 randomized controlled trials. Blood . 2020;136(9):1091-1104. 13. Covut F, Ahmed R, Chawla S, et al . Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol . 2021;193(6):1213-1219. 14.Li A, Wu Q, Luo S, et al . Derivation and validation of a risk assessment model for immu nomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw . 2019;17(7):840-847. 15.Maharaj S, Chang S, Seegobin K, Serrano-Santiago I, Zuberi L. Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multi ple myeloma. Expert Rev Anticancer er . 2017;17(7):585-591. 16. Zeng P, Schmaier A. Ponatinib and other CML tyrosine kinase inhibitors in thrombosis. Int J Mol Sci . 2020;21(18):6556. 17. Hochhaus A, Saglio G, Hughes TP, et al . Long-term bene ts and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia . 2016;30(5):1044-1054. 18. Qi WX, Min DL, Shen Z, et al . Risk of venous thromboembolic events associated with VE GFR-TKIs: a systematic review and meta-analysis. Int J Cancer . 2013;132(12):2967-2974. 19.Farooq MZ, Mathew J, Malik S, et al . Risk of arterial thromboembolic events (ATEs) with tyrosine kinase inhibitors (TKIs) used in renal cell carcinoma: a systematic review and me ta-analysis. J Clin Oncol . 2019;37(suppl 15):e13119-e13119. 20. Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. e double-edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep . 2012;14(4):295-306. 21.Mincu RI, Mahabadi AA, Michel L, et al . Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Networking Open . 2019;2(8):e198890. Copyright © 2023 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.